Epidermal Growth Factor in the Brain: A Promising Biomarker for Depression

Short title: Epidermal Growth Factor and Depression

Shu-xian Xu, M.D. & Ph.D.[1†]; Honggang Lyu, M.D.[1†]; Mian-mian Chen, M.D.[1]; Kun Li, M.D.[1]; Lihua Yao, M.D.[1]; Chao Wang, M.D. & Ph.D.[1]; Xin-hui Xie, M.D. & Ph.D.[1]*; Zhongchun Liu, M.D. & Ph.D.[1,2]*

Affiliations:

1. Department of Psychiatry, Renmin Hospital of Wuhan University, Wuhan, Hubei, PR China

2. Taikang center for life and medical sciences, Wuhan University, Wuhan, PR China

[†]These authors have contributed equally to this work.

*Corresponding authors:

Zhongchun Liu: Address: 1) Department of Psychiatry, Renmin Hospital of Wuhan University, No. 99 Jiefang Road, Wuchang District, Wuhan, Hubei, PR China. ZIP: 430060. Telephone: 86-8804191181399. 2) Taikang center for life and medical sciences, Wuhan University, Wuhan, PR China. ZIP: 430071. E-mail: zcliu6@whu.edu.cn

Xin-hui Xie: Address: 1) Department of Psychiatry, Renmin Hospital of Wuhan University, No. 99 Jiefang Road, Wuchang District, Wuhan, Hubei, PR China. ZIP:

23   430060. Telephone: 86-8804191181399. E-mail: xxh.med@gmail.com

Abstract

Background: This study aimed to examine the neurotrophic factors secreted from brain in depression by analyzing astrocyte-derived extracellular vesicles (ADEVs) isolated from plasma, and to explore the causal relationship between the expression of neurotrophic factors in the brain and depression.

Methods: A total of 40 patients with treatment-resistant depression (TRD) and 35 matched healthy controls (HCs) were recruited at baseline, and 34 TRD patients completed the post-electroconvulsive therapy (ECT) visits. The concentrations of five neurotrophic factors in ADEVs were measured. A correlation analysis was performed between neurotrophic factors in ADEVs and neurogenesis marker doublecortin (DCX) in neuron-derived extracellular vesicles (NDEVs). Subsequently, Mendelian randomization (MR) study and cell experiments were conducted.

Results: Our findings revealed a decrease in the level of epidermal growth factor (EGF) in ADEVs among TRD patients, with an increase observed post-ECT. The corrected area under the curve for EGF were larger than those for other neurotrophic factors: 0.99 (95% CI: 0.98-1.00). MR suggested that decreased expression levels of the *EGF* gene in the cortex constitute a risk factor for depression. We observed a positive correlation between the levels of EGF in ADEVs and DCX in NDEVs. Subsequently, cell experiments suggested that EGF can activate EGF receptor (EGFR) to trigger the PI3K-Akt pathway, participating in the promotion of DCX.

Conclusions: This study provides the *in vivo* evidences supporting that a reduction in EGF levels in the central nervous system could potentially contribute to depression

47 and serve as a biomarker for it. Additionally, the EGF/EGFR signaling pathway may

48 be involved in regulating early neurogenesis traits in depression.

50 **Keywords:** treatment-resistant depression; neurotrophic factors; astrocyte-derived

51 extracellular vesicle; neurogenesis; Mendelian randomization

Introduction

Major depressive disorder (MDD) is among the most prevalent mental disorders, marked by significant and enduring depression, loss of interest, and anhedonia[1,2]. It is also a leading cause of disability worldwide and contributes substantially to the global burden of disease[3].

Various hypotheses have been proposed to explain the underlying causes of depression[4,5]. Among them, the neurotrophic hypothesis of depression suggests that MDD-related synaptic and brain changes are primarily due to disrupted neurotrophic support[5]. Neurotrophic factors are of major importance because it modulates the plasticity and neurogenesis, inhibits cell death cascades and increases cell survival proteins that are responsible for proliferation and maintenance of central nervous system (CNS) neurons[4,6].

Astrocytes, known for their critical role in regulating neurotrophic factors and gliotransmitters that maintain brain homeostasis[7,8], may potentially contribute to the neuropathology of depression[9,10]. Astrocytes produce various neurotrophic factors, including brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), epidermal growth factor (EGF), fibroblast growth factor (FGF), insulin-like growth factor (IGF-1), vascular endothelial growth factor (VEGF), and nerve growth factor (NGF), all of which are implicated in the etiology and treatment of depression[11,12]. Among them, EGF is a protein that could be valuable for the early diagnosis and treatment assessment of depression. For instance, MDD patients with the rs11569017-TT genotype showed low plasma levels of EGF when

compared to controls[13]. MDD patients exhibit reduced EGF receptor *ErbB3*

expression, which increases and correlates with clinical improvement following 12

weeks of antidepressant treatment [14]. This suggests that investigating variations in the

EGF gene and their receptor expression could serve as a clinical predictor of recovery

in depression.

Unfortunately, research on other neurotrophic factors in depression remains

limited, with inconsistent findings. Peripheral blood samples, used in many previous

studies[15], might not accurately reflect brain neurotrophic factor levels due to their

widespread expression in various tissues[16-18]. Investigating these factors directly

within the brain is likely crucial for a deeper understanding of depression. The

difficulty of directly measuring neurotrophic factor levels in the CNS hinders the

acquisition of *in vivo* molecular evidence in patients with MDD. However, recent

breakthroughs in isolating brain-derived extracellular vesicles (EVs) offer a

revolutionary non-invasive approach for assessing CNS status *in vivo*. These EVs

hold immense promise as a "liquid biopsy" to evaluate molecular alterations within

the brain[19-21].

In this study, we initially found a decrease in the level of EGF in

astrocyte-derived extracellular vesicles (ADEVs) among treatment-resistant

depression (TRD) patients compared to controls, with an increase observed

post-electroconvulsive therapy (ECT). Subsequently, a Mendelian randomization (MR)

study was conducted to explore the causal effect of *EGF/EGF receptor (EGFR)* gene

expression on depression from a genetic perspective. As we also observed a positive

correlation between EGF levels in ADEVs and the early neurogenesis marker doublecortin (DCX) in neuron-derived extracellular vesicles (NDEVs). Cell experiments using SH-SY5Y cells were then performed to investigate the relationship between EGF and DCX.

Methods

Participants details

This observational longitudinal cohort was conducted at Renmin Hospital of Wuhan University in accordance with the Declaration of Helsinki[22] as our previous study[23,24]. The Human Ethics Committee approved the study protocol. Patients or their legal guardians provided informed consents. This report follows the STrengthening the Reporting of Observational studies in Epidemiology (STROBE) statement[25].

A total of 40 patients with TRD and 35 age-, and sex-matched healthy controls (HCs) were recruited. Subjects were excluded if they had comorbidity with other major psychiatric disorders. The HCs were required to be in good physical health, with no personal or first-degree family history of psychiatric disorders.

Thirty-four patients with TRD completed the post-ECT visits. Six milliliters of blood were drawn at baseline (T1), and 24 hours after the final ECT session (T2) to mitigate acute treatment effects. Cohort details and ECT procedures can be found in supplementary materials and our previous studies[23,24].

Isolation and confirmation of ADEVs

We employed different isolation methods for ADEVs used in protein measurements

and cell treatments. A two-step ADEVs protocol based on our prior work[24] was used

for protein analysis. In contrast, ADEVs for cell treatment underwent

ultracentrifugation (UC)[26] to isolate the total plasma EVs, followed by the same

immunoprecipitation method to isolate ADEVs. This approach avoided potential

contamination and cellular effects associated with polymer precipitation methods

commonly used in clinical settings. Confirmation of ADEV isolation was performed

using transmission electron microscopy (TEM), nanoparticle tracking analysis (NTA),

and western blotting. Please refer to the supplementary materials and our previous

studies[24] for more details.

Protein measurements in ADEVs

The levels of CD81, an EV marker, was measured using enzyme-linked

immunosorbent assay (ELISA) kit (American Research Products Inc., Catalog#

CSB-EL004960HU). Neurotrophic factors BDNF, FGF-2, GDNF, EGF and NGF-β in

ADEVs were measured using 5-Plex Human ProcartaPlex™ Panel (Thermo Fisher

Scientific).

Causal genetic evidence from Mendelian randomization

A MR study was conducted to validate the association between the neurotrophic

factors identified above and depression from a genetic perspective. By utilizing

genetic variants as instrumental variables, MR can provide more robust causal

inference between exposures and outcomes compared to traditional observational studies, thereby mitigating common confounding factors such as residual confounding, reverse causation bias, and measurement error. In this study, we leveraged brain-tissue specific expression quantitative trait loci (eQTL) data and genome-wide association study (GWAS) summary statistics on depression to perform two-sample MR (**sFigure 1**). Wald ratio and inverse variance weighting (IVW) were employed as the primary analytical methods in the main analysis. Additionally, sensitivity analyses were conducted. Details are provided in the supplementary materials.

Culture and treatments of SH-SY5Y cells

The SH-SY5Y cell line was obtained from Wuhan Procell Biotech Co., Ltd., China. These cells were cultured in basic DMEM/F-12 medium (Gibco, Catalog# C11330500BT) supplemented with 10% fetal bovine serum (FBS, WISENT, Catalog# 086-150) and 100 U/ml Penicillin-Streptomycin (Gibco, Catalog# 15140122) under 5% CO_2 at 37 °C. The medium was changed every 2-3 days, and when the cell density reached 80-90%, they were passaged at a 1:3 ratio.

Next, the well-growing SH-SY5Y cells were seeded in a 6-well plate at a density of 6 $*10^5$ cells per well with 2.5 ml medium for 24 hours. All cells used in the experiment were in the logarithmic growth phase. The cells were divided into two groups: the HC group (treated with ADEVs from 6 HCs) and the TRD group (treated with ADEVs from 6 patients with TRD). The EGF levels in ADEVs from HCs were higher than those in TRD. ADEVs were diluted with culture medium to a final

concentration of 20 μg/ml. After incubating with the respective agents for 24 hours,

the cells were harvested for subsequent analysis.

Furthermore, we performed another experiment, the well-growing SH-SY5Y

cells were seeded in a 6-well plate at a density of 6 *10^5 cells per well with 2.5 ml

medium for 24 hours. All cells used in the experiment were in the logarithmic growth

phase. Recombinant human EGF protein was diluted to a final concentration of 10

ng/ml to treat SH-SY5Y cells. The control group received an equal volume of growth

medium instead of the EGF solution. After 24 hours of treatment, the cells were

harvested for analysis.

Western blotting

Previous studies found that EGF binds to its receptor EGFR, activating the PI3K-Akt

and MAPK-Erk pathways which are crucial for neurogenesis in depression[27-29].

Therefore, we analyzed the proteins in these two pathways.

The following proteins were detected in SH-SY5Y cells: DCX (Abcam, Catalog#

ab207175), GAPDH (Huabio, Catalog# HA721131), EGFR (Affinity, Catalog#

AF6043), Phospho-EGFR (Tyr1068) (Affinity, Catalog# AF3045), Akt (Cell

Signaling, Catalog# 9272S), Phospho-Akt (Ser473) (Cell Signaling, Catalog# 4060S),

PI3K p85 (Affinity, Catalog# AF6241), Phospho-PI3K p85 (Affinity, Catalog#

AF3241), Erk1/2 (Cell Signaling, Catalog# 9102S), Phospho-Erk1/2 (Thr202/Tyr204)

(Cell Signaling, Catalog# 4370T).

Statistical analyses

For the clinical data, in the main analysis of protein levels in ADEVs at baseline, following the MIESV 2018[30], the outcomes were defined as the ratio of protein concentrations to CD 81 concentrations. General linear models (GLMs) were used to examine differences between two groups. In the GLMs, we set the outcomes as dependent variables and group as the independent variable, while controlling for covariates for sex and age. To represent the differences between the two groups, we used model-fitted estimated marginal means (EMMs) and their corresponding 95% confidence intervals (CIs). Additionally, to ensure robustness, a sensitivity analysis was conducted, with protein concentration levels per 1 ml plasma set as dependent variables. Receiver operating characteristic curves (ROCs) and corrected area under the curve (AUC) were employed to further explore the potential of these neurotrophic factors in ADEVs as biomarkers. In the exploratory analysis, Spearman coefficient was used to examine the correlation between EGF in ADEVs and DCX in NDEVs (as reported in our previous report[23]). For the comparisons between pre- and post-ECTs (paired longitudinal data), paired t-tests were used, with Cohen's d and its associated 95% CIs utilized to quantify effect sizes. Similar to the comparisons at baseline, a sensitivity analysis was conducted with the concentrations of protein levels per 1 ml plasma as dependent variables. False discovery rate (FDR) correction (Benjamini and Hochberg method) was employed to mitigate false positive outcomes. In comparisons of data from cell experiments, the Wilcoxon tests were employed. A two-tailed p-values less than 0.05 was considered significant. All statistical analyses were

performed using R version 4.1.0 (R Project for Statistical Computing) within Rstudio

version 1.4.1106 (Rstudio).

Results

EGF levels in ADEVs represent a promising potential biomarker for depression

Among 40 patients with TRD, six patients either did not undergo ECT treatment or

did not complete the post-ECT visit. Detailed baseline characteristics of the

participants was provided in **sTable 1**.

At baseline, the level of EGF in the TRD group was significantly lower than in

the HC group. This effect was consistent across different normalization methods.

Changes in other neurotrophic factors were more variable and yielded different

outcomes depending on the normalization method used (**Table 1** and **Figure 1**). The

AUCs for EGF were larger than those for other neurotrophic factors, with values of

0.99 (95% CI: 0.98-1.00) and 0.93 (95% CI: 0.86-0.99), respectively (**Figure 1**). This

indicates that EGF in ADEVs has a strong discrimination ability. Additionally, the

EGF level in ADEVs showed a positive correlation ($\rho = 0.38$, $p < 0.001$) with the

DCX level in NDEVs (**sFigure 2**).

Following ECT, there was a significant increase in EGF levels, this effect was

also consistent across different normalization methods (**Table 2** and **Figure 2**). In

summary, among the five neurotrophic factors tested, EGF showed the most robust

results both at baseline and in terms of changes before and after ECT.

Causal influence of brain-specific *EGF* gene expression on depression

Given the significant correlation between EGF expression and depression above, we employed MR to investigate the causal influence of brain-tissue specific *EGF* and *EGFR* genes expression on depression. Adhering to MR assumptions, we identified cis-eQTL data for *EGF* and *EGFR* genes in the brain cortex, respectively (**sTable 2**). Our MR analysis suggests that decreased expression of the *EGF* gene in the cortex may be a potential risk factor for depression (Wald ratio OR= 0.95, p = 0.009) (**sFigure 3**). However, neither method found a significant causal relationship between *EGFR* and depression.

Subsequently, we attempted to identify potential mechanistic pathways between *EGF/EGFR* genes and depression through MELODI Presto[31]. The analysis revealed that potential intermediary factors between these genes and depression were primarily associated with metabolic processes, cellular function, and neurological disorders. Interestingly, the results suggest an overlap between the *EGF*-depression interaction and the serotonin transporter pathway, potentially implicating *EGF* as a target for antidepressant development (**sTable 3**).

EGF activates EGFR to participate in the promotion of DCX expression

ADEVs purified using UC were confirmed via TEM, NTA, and western blotting validating successful ADEVs collection (**sFigure 4**).

As shown in **Figure 3A-F**, after 24 hours of intervention with ADEVs from patients with TRD and HCs, the expression level of the DCX protein in SH-SY5Y

cells intervened by ADEVs in the HC group showed a significant increase compared

to the TRD group ($p = 0.009$). Moreover, there was a significant increase in the

phosphorylation level of the EGFR ($p = 0.041$), along with simultaneous increases in

the phosphorylation levels of downstream pathway proteins PI3K ($p = 0.004$) and Akt

($p = 0.015$). However, there was no significant difference in the phosphorylation level

of Erk between the two groups ($p = 0.818$).

Following a 24-hour intervention with recombinant human EGF (**Figure 3G-L**),

the expression level of the DCX protein in SH-SY5Y cells significantly increased

compared to the control group ($p = 0.041$), accompanied by a significant elevation in

the phosphorylation level of EGFR ($p = 0.015$). Furthermore, the phosphorylation

levels of downstream pathway proteins PI3K ($p = 0.015$) and Akt ($p = 0.004$) were

also significantly increased concurrently. Nonetheless, there was no significant

difference in the phosphorylation level of Erk between the two groups ($p = 0.240$).

Discussion

Our study, using plasma ADEVs, indicates that decreased levels of EGF in the CNS

could serve as a biomarker for depression. Subsequently, MR results suggest that

decreased expression of the *EGF* gene in the cortex may contribute to the

development of depression. We also discovered a positive correlation between EGF

levels in ADEVs and DCX, suggesting that the EGF/EGFR signaling pathway may

play a role in regulating early neurogenesis traits in depression.

This study's strength lies in directly acquiring CNS evidences through ADEVs

and MR based on brain-tissue data, bypassing limitations of peripheral sources. Neurotrophic factors, like EGF, are often found at higher levels in peripheral tissues compared to the brain[17,18]. This widespread expression can confound results when solely using peripheral measures, a common limitation in depression studies. Additionally, the blood-brain barrier further complicates assessing CNS neurotrophic factors[32]. Therefore, our study offered valuable insights into the brain-specific relationship between neurotrophic factors and depression.

EGF and depression

Previous research on EGF and depression has yielded conflicting results. While one study found elevated EGF levels in adolescents with depression or bipolar disorder[33], another study focusing on elderly patients did not detect differences compared to HCs[34], consistent with another case-control study[35]. Additionally, two studies reported decreased peripheral blood EGF levels in depressed patients[13,36], consistent with findings of downregulated *EGF* mRNA levels in peripheral blood[37]. Additionally, cognitive alterations in MDD patients have been associated with the SNP rs2250724 of *EGF* gene[38].

Heterogeneity in EGF findings likely stems from several factors. First, variations in study populations can influence results. Serum EGF levels demonstrably decline with age[39], highlighting potential age-related heterogeneity. Second, comorbid conditions like anxiety might confound EGF expression. A study reported elevated EGF in patients with mild to moderate depression and anxiety[40], while others found

decreases in depression without anxiety[13,36]. Most importantly, previous research has

primarily focused on assessing EGF levels in peripheral blood, where they can be

influenced by various tissues[17]. This highlights the importance of directly assessing

EGF expression within the CNS, precisely the approach employed in our study. We

utilized ADEVs for the first time to detect EGF within the brains of depression

patients, and observed a significant decrease in EGF levels in TRD patients compared

to HCs. ROC curve analyses revealed high sensitivity and specificity of EGF in

ADEVs in identifying TRD, suggesting it as a promising biomarker for depression.

Our study further revealed that levels of EGF in ADEVs increased following

ECTs in patients with depression. Earlier studies have observed acute changes in EGF

levels after ECT. For example, one study reported a significant decrease in serum

EGF concentrations following ECTs[41], while another focusing on schizophrenia

showed no change in serum EGF levels between antipsychotic therapy alone and

combined ECT and antipsychotic treatment[42]. Notably, these prior studies relied on

peripheral EGF measurements, which may not reflect central EGF dynamics.

However, our findings, based on ADEVs which directly reflect the CNS, suggest EGF

as a potential marker for ECT response, highlighting the importance of CNS-level

assessment for understanding and treating depression.

Additionally, our MR analysis indicated that genetically predicted decreases in

EGF gene expression constitute a potential risk factor for depression, further

supporting our clinical observations. As eQTL effects on gene expression can vary

depending on the tissue examined, potentially introducing confounding factors and

leading to incorrect inferences. To address this limitation, we specifically investigated

the causal relationship between *EGF* eQTLs derived from brain-tissue specifically in

the cortex and depression. To strengthen our results, we used the MELODI Presto

analysis tool to further prioritize the *EGF* gene, highlighting its potential interactions

with antidepressive agents. This provides additional evidence supporting the

involvement of *EGF* in the mechanisms of antidepressant activity. This approach

offers insights into the biological pathways linking *EGF* and depression, indicating

that changes in the *EGF* expression could play a crucial role in the pathogenesis of

depression.

The observed genetic associations with reduced *EGF* expression reinforce the

need for additional preclinical studies to investigate how *EGF*-based interventions

might benefit patients with depression, and they also shed light on how *EGF*-related

pathways contribute to the onset and treatment of depression.

EGF/EGFR, neurogenesis and depression

Our previous study using NDEVs, firstly provided human *in vivo* evidence of

reduced markers of early neurogenesis DCX in patients with TRD, and observed

increased traits of immature neurons following ECT[23]. One potential mechanism

linking neurogenesis impairments with depression is through the loss of neurotrophic

factors and the disruption of their associated signaling pathways[5]. This study

discovered a notable positive correlation between EGF levels in ADEVs and DCX

levels in NDEVs. This finding suggests a potential link between EGF and early

neurogenesis. Then, we validated that ADEVs from HCs, with higher EGF levels,

increased DCX expression in SH-SY5Y cells compared to ADEVs from patients with

TRD. Similarly, EGF protein alone also stimulated DCX expression in SH-SY5Y

cells, potentially via the EGFR-PI3K-Akt pathway.

Astrocytes are the predominant cell type within the neurogenic niche, creating a

specialized environment for neurogenesis[43]. Previous studies have found that

astrocytes can secret EGF to increase neurogenesis[8,44]. EGF can promotes the

differentiation, maturation, and survival of various neurons, exerting neuromodulatory

effects on different types of neurons in the CNS[44]. The exogenous EGF has specific

effects on precursor cells *in vivo*[45]. Administering EGF into the ventricles for 2 weeks

expands precursor cell populations in the subventricular zone (SVZ), decreases the

total number of newborn neurons reaching the olfactory bulb, and significantly

increases the production of olfactory bulb astrocytes. Moreover, EGF increases the

number of newborn cells in the striatum either by migrating SVZ cells or by

stimulating local precursor cells, while also boosting the number of newborn glial

cells and reducing newborn neurons[46]. These findings illuminate EGF's role in

neurogenesis, and emerging evidence suggests that neurogenesis may play a role in

depression[47].

However, there is limited research exploring the relationship between EGF and

neurogenesis in depression. One study shown that FGF, EGF, BDNF, ketamine,

melatonin and the ketamine/melatonin combination stimulate neurogenesis and cell

cluster formation in cultured human olfactory neuronal precursors, thus offering

insights into the mechanism underlying their antidepressant effects[48]. Once EGF binds

to its receptor, EGFR, it forms a homodimer, which undergoes autophosphorylation in

the intracellular kinase domain, activating signaling cascades within the cell and even

in the nucleus[49]. Upon EGFR activation, the main downstream signaling pathways

include the PI3K-Akt pathway, the Ras-Raf-MAPK-Erk pathway, and the JAK/STAT

signaling pathway[29]. Studies have shown that the PI3K-Akt and MAPK-Erk signaling

pathways play crucial roles in neurogenesis, with several therapeutic targets for

depression acting on these pathways to promote neuronal growth and survival[27,28].

Our findings suggest that EGF might exert its effect on early neurogenesis in

depression by specifically activating the EGFR, which in turn triggers the PI3K-Akt

pathway. This activation pattern contrasts with the MAPK-Erk pathway, often

implicated in other cell growth and differentiation processes, indicating that the

selective activation of PI3K-Akt by EGF could be a distinctive mechanism through

which early neurogenesis is influenced in the context of depression. ECT may

stimulate this signaling pathway by promoting EGF secretion, leading to increased

early neurogenesis and potentially achieving antidepressant effects.

EV, a candidate key mediator in mediating EGF-neurogesis signaling

During the process of EGF/EGFR signaling, EVs may play a significant role.

EVs derived from neurons and neuroglial cells exert crucial bidirectional regulatory

effects in the physiological and pathological processes of the CNS[50]. These nanoscale

messengers not only ferry information from neurons to glial cells but also mediate the

reverse pathway, influencing neuronal function and establishing a dynamic intercellular network[20]. For instance, neurons can transfer miR-124b to astrocytes via EVs, enhancing the expression of glutamate transporter-1 in astrocytes, thereby regulating synaptic plasticity[51]. Additionally, ADEVs can enhance neuronal survival under ischemic and hypoxic conditions by delivering antiviral proteins[52]. Regarding our study, results of cell experiments suggest a possible antidepressant mechanism between astrocytes and neurogenesis, EGF carried by ADEVs activates the EGFR signaling pathway (including PI3K-Akt) in neurons, thereby promoting neuronal proliferation and growth.

This study proposes a novel framework for investigating CNS diseases in human subjects. By leveraging brain-derived extracellular vesicles (BDEVs), we can gain initial insights into the *in vivo* CNS state, facilitating the study of real-world pathological conditions. Furthermore, complementing BDEV analysis with *in vitro* cell experiments offers a comprehensive understanding of CNS biology. Additionally, the potential of EVs as drug delivery vehicles, with their ability to cross the blood-brain barrier and target specific cell types, opens exciting avenues for developing targeted therapeutic strategies for CNS diseases.

Limitations

This study has several limitations. Firstly, the limited quantity of ADEVs restricted high-throughput omics analyses, also hindering the detection of additional neurotrophic factors. Additionally, plasma ADEVs represent the entire brain,

precluding identification of specific neurotrophic factor source regions. Elucidating

these regional origins is helpful for understanding their roles in depression. Secondly,

for the MR study, the major GWAS data populations were predominantly European,

necessitating further validation of these MR findings in other populations. Also, the

limited number of instruments for cis-eQTL data from cortex tissue and other brain

tissues to investigate their association with depression, warranting further examination

in future studies. Furthermore, large-scale independent tissue-specific eQTL datasets

and employing additional genetic methods like transcriptome-wide association

studies[53] to estimate gene expression effects on depression should be considered in

future studies. We look forward to future research addressing this issue more

specifically. Thirdly, for cell experiments, resource constraints necessitated using the

SH-SY5Y cell line instead of primary neural stem cells, potentially compromising the

accuracy of neurogenesis data. Future studies should prioritize neural stem cells for a

more faithful representation of neurogenesis processes. Additionally,

serum-containing media hindered precise control over EGF levels, potentially

influencing our results. Employing serum-free media would enhance experimental

control. Finally, the complex composition of ADEVs limited our ability to identify the

specific pro-neurogenic molecule(s). Future studies isolating and analyzing individual

ADEV components are necessary to pinpoint the molecules responsible for the

observed increase in neurogenesis.

Conclusions

This study provides *in vivo* evidence for a potential role of reduced CNS EGF

levels in TRD patients, suggesting EGF as a promising biomarker. Then using MR,

we revealed a causal influence of low brain-specific *EGF* gene expression on

depression. Furthermore, our findings highlight the involvement of the EGF/EGFR

signaling pathway in regulating early neurogenesis, a process implicated in depression.

These insights may offer critical insights for developing novel antidepressant

therapies targeting the EGF/EGFR pathway using EVs.

Acknowledgements

This work was supported by grants from the National Natural Science Foundation of China (U21A20364). No funding was received from commercial organizations.

Conflict of interest disclosure

The authors declare no competing interests.

Authors' contributions

SXX conducted methodology, investigation, data curation, and contributed to the original draft and conceptualization. HL contributed to data curation and participated in manuscript review and editing. MMC and KL conducted investigation and data curation. LY and CW participated in manuscript review and editing. XHX provided conceptualization, performed formal analysis, visualization and supervision. ZL provided project administration, supervision, and acquired funding.

References

1. Otte C, Gold SM, Penninx BW, et al. Major depressive disorder. *Nat Rev Dis Primers*. Sep 15 2016;2:16065. doi:10.1038/nrdp.2016.65

2. Diseases GBD, Injuries C. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet*. Oct 17 2020;396(10258):1204-1222. doi:10.1016/S0140-6736(20)30925-9

3. Friedrich MJ. Depression Is the Leading Cause of Disability Around the World. *JAMA*. Apr 18 2017;317(15):1517. doi:10.1001/jama.2017.3826

4. Chopra K, Kumar B, Kuhad A. Pathobiological targets of depression. *Expert Opin Ther Targets*. Apr 2011;15(4):379-400. doi:10.1517/14728222.2011.553603

5. Fries GR, Saldana VA, Finnstein J, Rein T. Molecular pathways of major depressive disorder converge on the synapse. *Mol Psychiatry*. Jan 2023;28(1):284-297. doi:10.1038/s41380-022-01806-1

6. Skaper SD. Neurotrophic Factors: An Overview. *Methods Mol Biol*. 2018;1727:1-17. doi:10.1007/978-1-4939-7571-6_1

7. Cope EC, Gould E. Adult Neurogenesis, Glia, and the Extracellular Matrix. *Cell Stem Cell*. May 2 2019;24(5):690-705. doi:10.1016/j.stem.2019.03.023

8. Araki T, Ikegaya Y, Koyama R. The effects of microglia- and astrocyte-derived factors on neurogenesis in health and disease. *Eur J Neurosci*. Sep 2021;54(5):5880-5901. doi:10.1111/ejn.14969

9. Wang Q, Jie W, Liu JH, Yang JM, Gao TM. An astroglial basis of major

depressive disorder? An overview. *Glia*. Aug 2017;65(8):1227-1250. doi:10.1002/glia.23143

10. Rajkowska G, Stockmeier CA. Astrocyte pathology in major depressive disorder: insights from human postmortem brain tissue. *Curr Drug Targets*. Oct 2013;14(11):1225-36. doi:10.2174/13894501113149990156

11. Galvez-Contreras AY, Campos-Ordonez T, Lopez-Virgen V, Gomez-Plascencia J, Ramos-Zuniga R, Gonzalez-Perez O. Growth factors as clinical biomarkers of prognosis and diagnosis in psychiatric disorders. *Cytokine Growth Factor Rev*. Dec 2016;32:85-96. doi:10.1016/j.cytogfr.2016.08.004

12. Martin JL, Magistretti PJ, Allaman I. Regulation of neurotrophic factors and energy metabolism by antidepressants in astrocytes. *Curr Drug Targets*. Oct 2013;14(11):1308-21. doi:10.2174/1389450111314110009

13. Tian W, Zhang J, Zhang K, et al. A study of the functional significance of epidermal growth factor in major depressive disorder. *Psychiatr Genet*. Aug 2012;22(4):161-7. doi:10.1097/YPG.0b013e3283539550

14. Milanesi E, Minelli A, Cattane N, et al. ErbB3 mRNA leukocyte levels as a biomarker for major depressive disorder. *BMC Psychiatry*. Sep 18 2012;12:145. doi:10.1186/1471-244X-12-145

15. Wang H, Yang Y, Pei G, Wang Z, Chen N. Neurotrophic basis to the pathogenesis of depression and phytotherapy. *Front Pharmacol*. 2023;14:1182666. doi:10.3389/fphar.2023.1182666

16. Colitti M. Distribution of BDNF and TrkB isoforms in growing antler tissues of

red deer. *Ann Anat*. Sep 2017;213:33-46. doi:10.1016/j.aanat.2017.05.007

17. Fukuyama R, Shimizu N. Expression of epidermal growth factor (EGF) and the EGF receptor in human tissues. *J Exp Zool*. Jun 1991;258(3):336-43. doi:10.1002/jez.1402580309

18. The Genotype-Tissue Expression (GTEx) Portal https://www.gtexportal.org/home/.

19. Shi M, Sheng L, Stewart T, Zabetian CP, Zhang J. New windows into the brain: Central nervous system-derived extracellular vesicles in blood. *Prog Neurobiol*. Apr 2019;175:96-106. doi:10.1016/j.pneurobio.2019.01.005

20. Saint-Pol J, Gosselet F, Duban-Deweer S, Pottiez G, Karamanos Y. Targeting and Crossing the Blood-Brain Barrier with Extracellular Vesicles. *Cells*. Apr 1 2020;9(4)doi:10.3390/cells9040851

21. Brenna S, Krisp C, Altmeppen HC, Magnus T, Puig B. Brain-Derived Extracellular Vesicles in Health and Disease: A Methodological Perspective. *Int J Mol Sci*. Jan 29 2021;22(3)doi:10.3390/ijms22031365

22. World Medical A. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. *JAMA*. Nov 27 2013;310(20):2191-4. doi:10.1001/jama.2013.281053

23. Xie XH, Xu SX, Yao L, et al. Altered in vivo early neurogenesis traits in patients with depression: Evidence from neuron-derived extracellular vesicles and electroconvulsive therapy. *Brain Stimul*. Jan-Feb 2024;17(1):19-28. doi:10.1016/j.brs.2023.12.006

24. Xu SX, Xie XH, Yao L, et al. Human in vivo evidence of reduced astrocyte activation and neuroinflammation in patients with treatment-resistant depression following electroconvulsive therapy. *Psychiatry Clin Neurosci*. Dec 2023;77(12):653-664. doi:10.1111/pcn.13596

25. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Lancet*. Oct 20 2007;370(9596):1453-7. doi:10.1016/S0140-6736(07)61602-X

26. Greening DW, Xu R, Ji H, Tauro BJ, Simpson RJ. A protocol for exosome isolation and characterization: evaluation of ultracentrifugation, density-gradient separation, and immunoaffinity capture methods. *Methods Mol Biol*. 2015;1295:179-209. doi:10.1007/978-1-4939-2550-6_15

27. Liu Q, Zhang J, Xiao C, et al. Akebia saponin D protects hippocampal neurogenesis from microglia-mediated inflammation and ameliorates depressive-like behaviors and cognitive impairment in mice through the PI3K-Akt pathway. *Front Pharmacol*. 2022;13:927419. doi:10.3389/fphar.2022.927419

28. Xia CX, Gao AX, Dong TT, Tsim KW. Flavonoids from Seabuckthorn (Hippophae rhamnoides L.) mimic neurotrophic functions in inducing neurite outgrowth in cultured neurons: Signaling via PI3K/Akt and ERK pathways. *Phytomedicine*. Jul 2023;115:154832. doi:10.1016/j.phymed.2023.154832

29. Wee P, Wang Z. Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways. *Cancers (Basel)*. May 17 2017;9(5)doi:10.3390/cancers9050052

30. Thery C, Witwer KW, Aikawa E, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. *J Extracell Vesicles*. 2018;7(1):1535750. doi:10.1080/20013078.2018.1535750

31. Elsworth B, Gaunt TR. MELODI Presto: a fast and agile tool to explore semantic triples derived from biomedical literature. *Bioinformatics*. May 1 2021;37(4):583-585. doi:10.1093/bioinformatics/btaa726

32. Thorne RG, Frey WH, 2nd. Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations. *Clin Pharmacokinet*. 2001;40(12):907-46. doi:10.2165/00003088-200140120-00003

33. Skibinska M, Kapelski P, Dmitrzak-Weglarz M, et al. Elevated Epidermal Growth Factor (EGF) as Candidate Biomarker of Mood Disorders-Longitudinal Study in Adolescent and Young Adult Patients. *J Clin Med*. Sep 8 2021;10(18)doi:10.3390/jcm10184064

34. Wu HE, Teixeira AL, Barroso L, et al. Epidermal growth factor and fibroblast growth factor-2 circulating levels in elderly with major depressive disorder. *Psychiatry Res*. Feb 2019;272:141-143. doi:10.1016/j.psychres.2018.12.084

35. Domenici E, Wille DR, Tozzi F, et al. Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections. *PLoS One*. Feb 11 2010;5(2):e9166. doi:10.1371/journal.pone.0009166

36. Sohan M, Qusar M, Shahriar M, Islam SMA, Bhuiyan MA, Islam MR. Association of reduced serum EGF and leptin levels with the pathophysiology of

major depressive disorder: A case-control study. *PLoS One*. 2023;18(7):e0288159. doi:10.1371/journal.pone.0288159

37. Woo HI, Lim SW, Myung W, Kim DK, Lee SY. Differentially expressed genes related to major depressive disorder and antidepressant response: genome-wide gene expression analysis. *Exp Mol Med*. Aug 3 2018;50(8):1-11. doi:10.1038/s12276-018-0123-0

38. Tian WM, Zhang KR, Zhang J, Shen Y, Xu Q. Association between the epidermal growth factor gene and intelligence in major depression patients. *Chin Med Sci J*. Jun 2010;25(2):105-8. doi:10.1016/s1001-9294(10)60031-4

39. Kjaer IM, Olsen DA, Alnor A, Brandslund I, Bechmann T, Madsen JS. EGFR and EGFR ligands in serum in healthy women; reference intervals and age dependency. *Clin Chem Lab Med*. Nov 26 2019;57(12):1948-1955. doi:10.1515/cclm-2019-0376

40. Memon AA, Sundquist K, Ahmad A, Wang X, Hedelius A, Sundquist J. Role of IL-8, CRP and epidermal growth factor in depression and anxiety patients treated with mindfulness-based therapy or cognitive behavioral therapy in primary health care. *Psychiatry Res*. Aug 2017;254:311-316. doi:10.1016/j.psychres.2017.05.012

41. Stelzhammer V, Guest PC, Rothermundt M, et al. Electroconvulsive therapy exerts mainly acute molecular changes in serum of major depressive disorder patients. *Eur Neuropsychopharmacol*. Oct 2013;23(10):1199-207. doi:10.1016/j.euroneuro.2012.10.012

42. Zhang X, Xiao W, Chen K, et al. Serum Epidermal Growth Factor is Low in Schizophrenia and Not Affected by Antipsychotics Alone or Combined With

Electroconvulsive Therapy. *Front Psychiatry*. 2020;11:104. doi:10.3389/fpsyt.2020.00104

43. Verkhratsky A, Matteoli M, Parpura V, Mothet JP, Zorec R. Astrocytes as secretory cells of the central nervous system: idiosyncrasies of vesicular secretion. *EMBO J*. Feb 1 2016;35(3):239-57. doi:10.15252/embj.201592705

44. Wong RW, Guillaud L. The role of epidermal growth factor and its receptors in mammalian CNS. *Cytokine Growth Factor Rev*. Apr-Jun 2004;15(2-3):147-56. doi:10.1016/j.cytogfr.2004.01.004

45. Kuhn HG, Winkler J, Kempermann G, Thal LJ, Gage FH. Epidermal growth factor and fibroblast growth factor-2 have different effects on neural progenitors in the adult rat brain. *J Neurosci*. Aug 1 1997;17(15):5820-9. doi:10.1523/JNEUROSCI.17-15-05820.1997

46. Kuhn HG, Dickinson-Anson H, Gage FH. Neurogenesis in the dentate gyrus of the adult rat: age-related decrease of neuronal progenitor proliferation. *J Neurosci*. Mar 15 1996;16(6):2027-33. doi:10.1523/JNEUROSCI.16-06-02027.1996

47. Berger T, Lee H, Young AH, Aarsland D, Thuret S. Adult Hippocampal Neurogenesis in Major Depressive Disorder and Alzheimer's Disease. *Trends Mol Med*. Sep 2020;26(9):803-818. doi:10.1016/j.molmed.2020.03.010

48. Estrada-Reyes R, Quero-Chavez DB, Alarcon-Elizalde S, et al. Antidepressant Low Doses of Ketamine and Melatonin in Combination Produce Additive Neurogenesis in Human Olfactory Neuronal Precursors. *Molecules*. Sep 1 2022;27(17)doi:10.3390/molecules27175650

49. Stoll SW, Stuart PE, Swindell WR, et al. The EGF receptor ligand amphiregulin controls cell division via FoxM1. *Oncogene*. Apr 21 2016;35(16):2075-86. doi:10.1038/onc.2015.269

50. Wu J, Li S, Zhang Y. Research progress in role of exosomes exosomes in mental disorders. *Zhong Nan Da Xue Xue Bao Yi Xue Ban*. May 28 2023;48(5):771-781. 外泌体在精神障碍中作用的研究进展. doi:10.11817/j.issn.1672-7347.2023.220379

51. Morel L, Regan M, Higashimori H, et al. Neuronal exosomal miRNA-dependent translational regulation of astroglial glutamate transporter GLT1. *J Biol Chem*. Mar 8 2013;288(10):7105-16. doi:10.1074/jbc.M112.410944

52. Guitart K, Loers G, Buck F, Bork U, Schachner M, Kleene R. Improvement of neuronal cell survival by astrocyte-derived exosomes under hypoxic and ischemic conditions depends on prion protein. *Glia*. Jun 2016;64(6):896-910. doi:10.1002/glia.22963

53. Gusev A, Ko A, Shi H, et al. Integrative approaches for large-scale transcriptome-wide association studies. *Nat Genet*. Mar 2016;48(3):245-52. doi:10.1038/ng.3506

Figure legends

Figure 1. Comparisons of target protein concentrations in astrocyte-derived extracellular vesicles (ADEVs) between treatment-resistant depression (TRD) and healthy control (HC) group at baseline. Note: n.s.: not significant; *p_false discovery rate (FDR) < 0.05; **p_FDR < 0.01; ***p_FDR < 0.001.

Figure 2. Changes of target protein concentrations in ADEVs between pre- and post-ECT in patients with TRD. Note: n.s.: not significant; $*p_{\text{false discovery rate (FDR)}} < 0.05$; $**p_{\text{FDR}} < 0.01$; $***p_{\text{FDR}} < 0.001$.

Figure 3. Western blotting results of cell expriments. A-F: After 24 hours of intervention with ADEVs from patients with TRD and HCs in SH-SY5Y cells, the expression levels of doublecortin (DCX) protein in the HC group significantly increased compared to the TRD group. The phosphorylation levels of EGFR, PI3K, and Akt also significantly increased, while there was no significant difference in the phosphorylation levels of Erk between the two groups. G-L: After 24 hours of intervention with ADEVs from patients with TRD and HCs in SH-SY5Y cells, the expression levels of DCX protein in the HC group significantly increased compared to the TRD group. The phosphorylation levels of EGFR, PI3K, and Akt also significantly increased, while there was no significant difference in the phosphorylation levels of Erk between the two groups. Note: n.s.: not significant; *p_{FDR} < 0.05; **p_{FDR} < 0.01.

649 Table 1. Baseline comparisons of neurotrophic factors in ADEVs between TRD and HC groups

variable	HC group (EMM (95% CI))	TRD group (EMM (95% CI))	Difference (95% CI)	p	p_{FDR}
Main analysis: Normalized to CD81 ratio					
BDNF	0.0025 (0.0022 to 0.0029)	0.0012 (0.0009 to 0.0015)	-0.0013 (-0.0018 to -0.0009)	<0.001	<0.001
EGF	0.0011 (0.001 to 0.0012)	0.0003 (0.0002 to 0.0004)	-0.0008 (-0.0009 to -0.0006)	<0.001	<0.001
FGF-2	0.0039 (0.0032 to 0.0045)	0.0031 (0.0025 to 0.0037	-0.0008 (-0.0016 to 0.0001)	0.097	0.097
GDNF	0.0167 (0.0145 to 0.0189)	0.0121 (0.01 to 0.0141)	-0.0047 (-0.0076 to -0.0018)	0.002	0.004
NGF-β	0.0043 (0.0036 to 0.0050)	0.0035 (0.0028 to 0.0042)	-0.0008 (-0.0017 to 0.0001)	0.094	0.097
Sensitive analysis: Normalized to 1 ml plasma					
BDNF	9.84 (8.16 to 11.52)	8.65 (7.1 to 10.2)	-1.19 (-3.41 to 1.03)	0.298	0.298
EGF	3.98 (3.62 to 4.34)	2.01 (1.67 to 2.34)	-1.97 (-2.45 to -1.5)	<0.001	<0.001
FGF-2	13.94 (10.56 to 17.32)	21.39 (18.27 to 24.51)	7.45 (2.98 to 11.92)	0.002	0.002
GDNF	60.55 (53.47 to 67.64)	82.77 (76.24 to 89.31)	22.22 (12.85 to 31.59)	<0.001	<0.001
NGF-β	15.42 (11.71 to 19.13)	24.56 (21.14 to 27.98)	9.14 (4.23 to 14.05)	<0.001	0.001

651 Table 2. Changes of neurotrophic factors in ADEVs of TRD after ECTs.

Variable	Change from baseline (95% CI))	Cohen's d (95% CI))	p	p_{FDR}
Main analysis: Normalized to CD81 ratio				
BDNF	0.00001 (-0.00022 to 0.00024)	0.01 (-0.33 to 0.36)	0.934	0.934
EGF	0.00027 (0.00019 to 0.00036)	1.14 (0.69 to 1.57)	<0.001	<0.001
FGF-2	-0.00047 (-0.00118 to 0.00024)	-0.23 (-0.58 to 0.11)	0.189	0.321
GDNF	0.00066 (-0.00101 to 0.00233)	0.14 (-0.2 to 0.48)	0.424	0.53
NGF-β	-0.00048 (-0.00122 to 0.00026)	-0.23 (-0.58 to 0.12)	0.193	0.321
Sensitive analysis: Normalized to 1 ml plasma				
BDNF	-1.31 (-3.03 to 0.41)	-0.27 (-0.61 to 0.08)	0.131	0.131
EGF	1.2 (0.74 to 1.67)	0.91 (0.5 to 1.31)	<0.001	<0.001
FGF-2	-5.7 (-9.63 to -1.76)	-0.51 (-0.87 to -0.15)	0.006	0.007
GDNF	-9.15 (-15.48 to -2.82)	-0.51 (-0.87 to -0.15)	0.006	0.007
NGF-β	-6.74 (-11.19 to -2.29)	-0.54 (-0.9 to -0.17)	0.004	0.007

655 **Supplementary materials**

657 **sFigure 1.** Mendelian randomization framework.

660 **sFigure 2.** The spearman coefficient between EGF in ADEVs and the DCX in

661 NDEVs.

Exposure	Methods	snp	OR (95% CI)	P-value
Cortex EGF gene expression				
	Wald ratio	rs2190907	0.95 (0.91 to 0.99)	0.009
	MR RAPS	rs2190907	0.95 (0.90 to 0.99)	0.021
Cortex EGFR gene expression				
	Wald ratio	rs73135226	1.00 (0.97 to 1.03)	0.985
	MR RAPS	rs73135226	1.00 (0.97 to 1.03)	0.986

sFigure 3. Results of Mendelian randomization study.

sFigure 4. Confirmation of ADEVs utilizing UC. A) The results of NTA show the diameter distribution of the EVs, which also corroborate with the prior knowledge of exosomes-like small EVs (peak diameter: 82.3 nm, concentration: $2.4*10^9$ particles/ml); B) The transmission electron microscopy image of ADEVs isolated from a health control, the image clearly shows the exosomes-like shape (orange arrows); C) Western blotting results of total EV (TEV), supernatant of TEV, and ADEV from one healthy control. Three exosomes markers, CD9, Alix, TSG 101, and an astrocyte marker glial fibrillary acidic protein (GFAP) was identified.

675   **sTable 1.** Baseline characteristics of included participants for clinical trial.

677   **sTable 2.** Genetic instruments for *EGF/EGFR* expression in brain tissues.

679   **sTable 3.** MELODI Presto results for *EGF/EGFR* genes and depression.

681   **Supplementary document:** Detailed Methods.

Changes after ECTs